Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables: 2023-2025

Historic Receivables for BioLineRx (BLRX) over the last 1 years, with Jun 2025 value amounting to $281,000.

  • BioLineRx's Receivables fell 92.67% to $281,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year change of. This contributed to the annual value of $4.0 million for FY2024, which is 232.83% up from last year.
  • BioLineRx's Receivables amounted to $281,000 in Q2 2025, which was down 85.37% from $1.9 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Receivables peaked at $4.0 million during Q3 2024, and registered a low of $281,000 during Q2 2025.
  • In the last 3 years, BioLineRx's Receivables had a median value of $3.3 million in 2024 and averaged $2.6 million.
  • Per our database at Business Quant, BioLineRx's Receivables surged by 232.83% in 2024 and then tumbled by 92.67% in 2025.
  • BioLineRx's Receivables (Quarterly) stood at $1.2 million in 2023, then surged by 232.83% to $4.0 million in 2024, then tumbled by 92.67% to $281,000 in 2025.
  • Its Receivables was $281,000 in Q2 2025, compared to $1.9 million in Q1 2025 and $4.0 million in Q4 2024.